Bruce 1994.

Methods	DESIGN Between‐patient Participant delivery ALLOCATION Random Method of randomisation: not reported Concealment: unclear BLINDING Double‐blind (participant/investigator) WITHDRAWAL/DROPOUT Described
Participants	N: 114 Treatment duration: 6 wks; FU: 6 wks LF: 15 (13.2%) BC: yes Age: 44.1 (14.6SD; range = 20 to 77) Gender (per cent men): 60.2% Severity: mean duration of current episode (days) = 142 (range = 0 to 601) Overall severity score (mean): 4.5 INCLUSION CRITERIA Stable plaque psoriasis Adults At least mild overall severity At least moderately severe plaque elevation EXCLUSION CRITERIA Pregnancy Lactation Inadequate contraception Sensitivity to test medications Recent topical, UV, or systemic treatment Recent involvement in other trials Planned sun exposure
Interventions	Calcipotriol ointment 0.005% BD (C) Fluocinonide ointment 0.05% BD (F)
Outcomes	Sign: scaling, erythema, plaque elevation Overall severity (Total Sign Score and per cent involvement) Investigator Global Assessment
Notes	Westwood Squibb Pharmaceuticals Inc. sponsored the trial. There was SD imputation (TSS).
Risk of bias
Bias	Authors' judgement	Support for judgement
Allocation concealment (selection bias)	Unclear risk	The trial reported insufficient details.
Blinding (performance bias and detection bias) All outcomes	Low risk	The trial was double‐blind (participant/investigator).
Randomisation method reported	Unclear risk	The trial did not report this.
Loss to follow up	Low risk	13.2%
Baseline assessments	Low risk	‐
Baseline comparability demonstrated	Low risk	‐